NCT07526961 2026-04-14
Real-World Outcomes of First-Line Nivolumab + Ipilimumab With Chemotherapy in Non-Small Cell Lung Cancer in Poland
Bristol-Myers Squibb
Completed
Clinical Trials
55 trialsNCT03158129 2026-04-06
Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT05136677 2026-01-23
CheckMate 6DW
Bristol-Myers Squibb
Phase 2 Completed
NCT04334759 2026-01-22
DREAM3R
PrECOG, LLC.
Phase 3 Completed
NCT03285321 2026-01-20
Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
Big Ten Cancer Research Consortium
Phase 2 Completed
NCT03575793 2026-01-20
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
Big Ten Cancer Research Consortium
Phase 1/2 Completed
NCT02998528 2026-01-06
CheckMate 816
Bristol-Myers Squibb
Phase 3 Completed
NCT03215706 2025-12-17
CheckMate 9LA
Bristol-Myers Squibb
Phase 3 Completed
NCT03469960 2025-11-18
DICIPLE
Intergroupe Francophone de Cancerologie Thoracique
Phase 3 Completed
NCT02477826 2025-10-30
CheckMate 227
Bristol-Myers Squibb
Phase 3 Completed
NCT03573947 2025-10-14
TOP1705
Duke University
Phase 2 Completed
NCT03126110 2025-08-14
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Completed
NCT04026412 2025-07-24
CheckMate73L
Bristol-Myers Squibb
Phase 3 Completed
NCT03739710 2025-06-15
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)
GlaxoSmithKline
Phase 2 Completed
NCT02922764 2025-03-26
A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer
Inspirna, Inc.
Phase 1 Completed
NCT03058289 2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2 Completed
NCT03262779 2025-01-09
Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer.
Yale University
Phase 2 Completed
NCT03043599 2024-12-20
Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT02046733 2024-11-08
STIMULI
ETOP IBCSG Partners Foundation
Phase 2 Completed
NCT04855929 2024-11-08
ANV419-001
Anaveon AG
Phase 1 Completed
NCT03752398 2024-07-05
DUET-3
Xencor, Inc.
Phase 1 Completed
NCT02899299 2024-05-21
CheckMate743
Bristol-Myers Squibb
Phase 3 Completed
NCT03001882 2024-05-20
CheckMate 592
Bristol-Myers Squibb
Phase 2 Completed
NCT05005273 2024-02-28
A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer
Bristol-Myers Squibb
Phase 2 Completed
NCT03083691 2024-01-17
BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer
Lung Cancer Group Cologne
Phase 2 Completed
NCT05041062 2024-01-03
A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma
University of Chicago
Phase 2 Completed
NCT02864251 2023-09-28
CheckMate722
Bristol-Myers Squibb
Phase 3 Completed
NCT03302234 2023-09-26
KEYNOTE-598
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03639714 2023-09-13
A Study of a Personalized Neoantigen Cancer Vaccine
Gritstone bio, Inc.
Phase 1/2 Completed
NCT03953235 2023-09-13
A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens
Gritstone bio, Inc.
Phase 1/2 Completed
NCT02658890 2023-08-28
An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread
Bristol-Myers Squibb
Phase 1/2 Completed
NCT02869789 2023-06-15
An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers
Bristol-Myers Squibb
Phase 4 Completed
NCT02659059 2023-04-05
CheckMate 568
Bristol-Myers Squibb
Phase 2 Completed
NCT03351361 2023-03-01
eNERGY
Rennes University Hospital
Phase 3 Completed
NCT02538666 2023-01-05
CheckMate 451
Bristol-Myers Squibb
Phase 3 Completed
NCT02039674 2022-11-08
MK-3475-021
Merck Sharp & Dohme LLC
Phase 1/2 Completed
NCT03241173 2022-09-27
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Completed
NCT03989362 2022-09-10
EMERGE
Jounce Therapeutics, Inc.
Phase 2 Completed
NCT02381314 2022-02-08
Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer
MacroGenics
Phase 1 Completed
NCT01454102 2021-10-12
Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)
Bristol-Myers Squibb
Phase 1 Completed
NCT01840579 2021-06-22
MK-3475-011
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01820754 2021-02-26
TOP1201 IPI
Duke University
Phase 2 Completed
NCT02716272 2021-02-10
MAPS2
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Completed
NCT03048474 2021-01-20
INITIATE
The Netherlands Cancer Institute
Phase 2 Completed
NCT02239900 2020-11-30
Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Completed
NCT03256136 2020-11-04
Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC
Massachusetts General Hospital
Phase 2 Completed
NCT03695835 2020-07-22
NIRPA
Gary Onik MD
Completed
NCT01450761 2020-07-08
Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone
Bristol-Myers Squibb
Phase 3 Completed
NCT01285609 2020-06-18
Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin
Bristol-Myers Squibb
Phase 3 Completed
NCT02221739 2020-05-11
Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)
NYU Langone Health
Phase 1/2 Completed